HepaRegeniX

Ulm, Germany

HepaRegeniX is developing drugs for treating acute and chronic liver diseases.

$24.3M raised

Apr 2025

Venture - Series Unknown

Biotechnology Health Care Life Science Therapeutics

Top Investors

HTGF (High-Tech Gruenderfonds)Wellington PartnersNovo HoldingsBoehringer Ingelheim Venture FundVesalius Biocapital Partners

Founder Contacts

19,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about HepaRegeniX

How much funding has HepaRegeniX raised?

HepaRegeniX has raised $24.3M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in April 2025.

Who are HepaRegeniX's investors?

HepaRegeniX's investors include HTGF (High-Tech Gruenderfonds), Wellington Partners, Novo Holdings, Boehringer Ingelheim Venture Fund, Vesalius Biocapital Partners.

Where is HepaRegeniX headquartered?

HepaRegeniX is headquartered in Ulm, Germany.

What does HepaRegeniX do?

HepaRegeniX is developing drugs for treating acute and chronic liver diseases.

What stage is HepaRegeniX at?

HepaRegeniX is at the Venture - Series Unknown stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated April 15, 2025.

MLA

"HepaRegeniX — Funding & Investors." VCBacked, April 15, 2025, https://www.vcbacked.co/company/heparegenix. Accessed June 7, 2026.

APA

VCBacked. (2025). HepaRegeniX — Funding & Investors. Retrieved June 7, 2026, from https://www.vcbacked.co/company/heparegenix

Wikipedia (cite web)

{{cite web |title=HepaRegeniX — Funding & Investors |url=https://www.vcbacked.co/company/heparegenix |website=VCBacked |access-date=June 7, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated April 15, 2025.

Similar Companies in Biotechnology